Related Experiment Video

Updated: Jul 8, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Targeted therapy of the insulin-like growth factor-1 receptor in cancer

Keren Paz1, Yaron R Hadari

  • 1Department of Tumor Biology, ImClone Systems Incorporated, New York, NY 10014, USA. keren.paz@imclone.com

Combinatorial Chemistry & High Throughput Screening
|January 29, 2008
PubMed

Insights

The insulin-like growth factor 1 receptor (IGF-1R) is crucial in cancer development. This review explores IGF-1R biology and targeted therapies, including antibodies and kinase inhibitors, for cancer treatment.

Area of Science:

  • Molecular oncology
  • Cancer biology
  • Pharmacology

Background:

  • Cancer pathogenesis is increasingly understood at the molecular level.
  • The type 1 insulin-like growth factor receptor (IGF-1R) system is implicated in carcinogenesis.
  • IGF-1R signaling pathways play a significant role in cancer development and progression.

Purpose of the Study:

  • To review the biology of the IGF-1R system in the context of cancer.
  • To discuss the development and therapeutic potential of IGF-1R antagonists.
  • To highlight agents targeting IGF-1R, including antibodies and small molecule inhibitors.

Main Methods:

  • Comprehensive literature review focusing on IGF-1R biology and cancer.
  • Analysis of molecular mechanisms underlying IGF-1R activation and signaling.
  • Evaluation of therapeutic strategies targeting the IGF-1R pathway.

Main Results:

  • The IGF-1R system is a validated target for cancer therapy due to its role in carcinogenesis.
  • Development of specific agents, including antibodies and tyrosine kinase inhibitors, targeting IGF-1R has advanced.
  • These IGF-1R inhibitors are under active clinical investigation for various cancers.

Conclusions:

  • The IGF-1R pathway represents a promising target for novel cancer therapeutics.
  • Targeted inhibition of IGF-1R offers a potential strategy for potent and specific cancer intervention.
  • Ongoing clinical trials will determine the efficacy and application of IGF-1R antagonists in cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...